Standard BioTools Q2 FY26 operating loss narrows 1% to $25.4 million; revenue falls 7.6% to $20.1 million - LAB News | RalliesStandard BioTools Q2 FY26 operating loss narrows 1% to $25.4 million; revenue falls 7.6% to $20.1 million
L
LAB• Q2 FY26 results
- Standard BioTools posted Q2 2026 revenue of $20.1 million, down 7.6% year-over-year.
- Operating loss narrowed 1% to $25.4 million, while GAAP net loss from continuing operations widened 21% to $21.5 million.
- Adjusted EBITDA loss shrank to $2.5 million from $16.1 million a year earlier, a year-over-year improvement of 84%.
- Cash, cash equivalents, restricted cash, short-term and long-term investments climbed to $541.1 million.
Merger and outlook
- The merger with Treeline Biosciences is progressing toward a stockholder vote, with closing anticipated before year-end 2026.
- Full-year revenue outlook was withdrawn.
•
